Financial Data and Key Metrics Changes - Consolidated adjusted EBITDA for Q4 2025 was $56.7 million, down $9.4 million year-over-year, primarily due to lower coke sales volumes and market conditions [9][10] - Full-year consolidated adjusted EBITDA was $219.2 million, a decrease of $53.6 million compared to the previous year [9][10] - The net loss attributable to SunCoke for Q4 2025 was $1 per share, down from $1.28 per share in Q4 2024, driven by one-time items totaling $0.85 per share net of tax [8] - Full-year net loss attributable to SunCoke was $0.52 per share, down from $1.64 per share in 2024, impacted by one-time items totaling $0.97 per share net of tax [8] Business Line Data and Key Metrics Changes - Domestic coke business delivered full-year adjusted EBITDA of $170 million, down $64.7 million from the prior year, affected by contract and spot coke sales mix changes and lower contract economics [10] - Industrial services segment, including Phoenix Global, delivered full-year adjusted EBITDA of $62.3 million, an increase of $11.9 million year-over-year, primarily due to the addition of Phoenix Global [11] - Corporate and other expenses increased by $800,000 year-over-year to $13.1 million, reflecting costs from legacy operations [11] Market Data and Key Metrics Changes - The domestic coke segment is expected to deliver adjusted EBITDA between $162 million and $168 million in 2026, with sales of approximately 3.4 million tons [16][18] - Industrial services adjusted EBITDA is projected to be between $90 million and $100 million in 2026, reflecting expectations for improved market conditions [19][20] Company Strategy and Development Direction - The company plans to utilize free cash flow to support capital allocation priorities, including paying down revolver balance and maintaining dividends [22] - Focus on seamless integration of Phoenix Global and exploring new growth opportunities across all business areas [23] - The company aims to maintain strong safety and environmental performance as a competitive advantage [22] Management's Comments on Operating Environment and Future Outlook - Management anticipates a meaningful recovery in 2026, supported by an optimized coke fleet and extended contracts [15] - The company expects to generate positive free cash flow in 2026, with gross leverage targeted around 2.45x, below the long-term target of 3x [15] - Management highlighted challenges in 2025 due to market conditions but remains optimistic about future performance [15] Other Important Information - The company returned approximately $41 million to shareholders via dividends in 2025 and plans to continue this in 2026 [7] - The integration of Phoenix Global is progressing well, with expectations for significant contributions in 2026 [15] Q&A Session Summary Question: Status of litigation with Algoma regarding contract breach - Management confirmed ongoing arbitration with Algoma, expecting to recover losses from the breach, which could amount to up to $70 million [28][29] Question: Anticipated EBITDA contribution from Phoenix Global - Management affirmed expectations of an annual EBITDA contribution of roughly $60 million from Phoenix Global [31] Question: One-time integration costs incurred with Phoenix Global - One-time costs included site closure costs of about $3.9 million and transaction costs of approximately $600,000 [32] Question: Permanence of Haverhill One closure and potential reopening - Haverhill One closure is permanent unless significant capital investment is made, which is not currently justified [40] Question: Expected improvement in tons handled in the industrial segment - Guidance includes a full year of the new KRT contract and modest recovery across both KRT and CMT [49]

Financial Data and Key Metrics Changes - Revenue for the second quarter was $116,000, compared to $0 in the same period last year, primarily from cost reimbursements under a collaboration agreement with Boehringer Ingelheim [6] - Total operating expenses increased to $7.4 million from $2.6 million in the prior year, driven by higher investments in obesity development programs and increased compensation costs [6][7] - Net loss for the quarter was $7.3 million, or $2.86 per share, compared to a net loss of $2.4 million, or $5.92 per share in the comparable period last year [8] - Cash and cash equivalents as of December 31, 2025, were $14.5 million, up from $1.3 million at September 30, 2025 [9] Business Line Data and Key Metrics Changes - The company is advancing its melanocortin-4 receptor-based obesity pipeline, focusing on rare syndromic and genetic obesity disorders [10] - The lead oral small molecule MC4R agonist, PL7737, is progressing through IND-enabling toxicology studies, with an IND submission planned for the first half of 2026 [11] - Next-generation selective melanocortin-4 receptor peptide agonists are also being developed, with an IND submission planned for the second half of 2026 [11] Market Data and Key Metrics Changes - The company regained compliance with NYSE American listing standards, and its common stock resumed trading under the symbol PTN [5][13] - The focus remains on rare neuroendocrine obesity disorders, including hypothalamic obesity and Prader-Willi syndrome, which represent significant unmet medical needs [10][12] Company Strategy and Development Direction - The company aims to deliver differentiated product profiles with a focus on enhancing patient tolerability and minimizing off-target effects [11] - A sub-licensing transaction for PL9643 provided approximately $3.8 million in upfront consideration, allowing the company to sharpen its focus on core obesity programs [12][13] - The company is positioned to pursue substantial long-term value creation through multiple partnerships and near-term milestones [13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the differentiation of their products, particularly regarding tolerability and safety profiles compared to existing treatments [17][34] - The company anticipates moving forward into phase II studies for both oral small molecules and long-acting peptides targeting hypothalamic obesity and Prader-Willi syndrome patients by mid-2027 [43] Other Important Information - The company completed an $18.2 million public offering, which significantly strengthened its balance sheet and provided capital for advancing its obesity pipeline [5][10] - The company expects its cash runway to extend beyond the quarter ending March 31, 2027 [9] Q&A Session Summary Question: What preclinical or translational signals give confidence in differentiation for PL7737? - Management highlighted the design of the compound to be more selective for the melanocortin-4 receptor, which should reduce hyperpigmentation and control GI side effects [17] Question: How will patient selection and endpoints be approached in the phase one study? - The focus will be on safety and confirming oral absorption, with weight reduction and control of hyperphagia as key parameters in the multiple-ascending dose study [19][20] Question: Is there an increased emphasis on Prader-Willi syndrome? - Management confirmed that while Prader-Willi has always been in the background, they are focusing on indications with substantial patient populations [21][22] Question: How will the oral small molecule and weekly injection be positioned? - Both products are seen as complementary, with each suited for different patient populations [24][25] Question: What is the anticipated cash flow and resource allocation for PWS studies? - Management indicated sufficient cash to move forward with both oral and peptide studies, with plans to initiate studies in PWS patients by mid-2027 [43] Question: How will GLP-1 therapies be integrated into product development? - Management anticipates that combination therapies will be necessary for optimizing treatment, particularly for patients with severe hyperphagia [48]

Financial Data and Key Metrics Changes - For Q4 2025, the company reported investment income of $5.9 million, or $0.86 per share, an increase from $5.4 million in the previous quarter [15] - Total expenses for the quarter were $2.5 million, or $0.37 per share, compared to $0.35 in the prior quarter [15] - Net investment income rose to $3.4 million, or $0.49 per share, up from $3 million, or $0.44 per share in Q3 [15] - The net loss for the quarter was $12.4 million, or $1.81 per share [16] - Total assets as of December 31, 2025, were $141.3 million, with total net assets of $98.6 million, resulting in a net asset value per share of $14.42, down from $16.89 as of September 30 [16][21] Business Line Data and Key Metrics Changes - The portfolio generated strong recurring cash flows totaling $9.8 million, or $1.44 per share, exceeding distributions and expenses by $0.41 per share, an increase from $8.7 million, or $1.28 per share in the prior quarter [16] - The weighted average gap yield of the portfolio decreased slightly to 12.99% at quarter end, compared to 13.07% as of September 30 [11] Market Data and Key Metrics Changes - The CLO equity market faced significant challenges in 2025, with industry returns estimated at -10% for the year [9] - The primary pressure on performance came from a substantial tightening of spreads in the underlying loans inside CLOs, approximately 34 basis points in the U.S. loan market [9] - The company observed a gradual slowing down in loan repricing prepayment speeds, with the ratio of CLO loan portfolios pricing above par decreasing from over 50% to about 30% [32] Company Strategy and Development Direction - The company remains optimistic about CLOs, viewing them as attractive investment opportunities compared to other asset classes, with a focus on disciplined portfolio management and opportunistic investments [6][7] - The company plans to utilize its data-driven approach to CLO equity investing to grow its portfolio thoughtfully [6] - The company aims to manage exposure to individual credits or sectoral weaknesses through its diversified portfolio, which consists of CLOs with reinvestment periods ending in 2026 and later [8][14] Management's Comments on Operating Environment and Future Outlook - Management highlighted a resilient macro environment with inflation reducing to central bank targets and a low leveraged loan default rate, indicating continued opportunities for CLO equity investing [7] - The company expects M&A activity to increase marginally and anticipates that the pressure from tightening loan spreads will reduce in the coming quarters [26][27] - Management expressed cautious optimism regarding an improving backdrop for the asset class, with expectations of less spread compression in 2026 compared to 2025 [10][11] Other Important Information - The company executed share issuances through its at-the-market equity issuance program, issuing 30,680 shares for net proceeds of approximately $0.5 million during the quarter [17] - Dividends of $0.22 per common share were distributed in October, November, December, and January, with plans for similar distributions in the following months [18] Q&A Session Summary Question: Can you comment on the investment environment in the primary versus secondary market? - Management noted opportunities in both markets but indicated a current overweight in the secondary market [24] Question: What are the refinancing and reset opportunities in your portfolio over the next few quarters? - Management mentioned multiple positions exiting their non-call periods, expecting upside in a tightening CLO liability spread environment [25] Question: Can you comment on the supply of new loans expected in 2026? - Management expects M&A activity to increase and anticipates a reduction in pressure from tightening loan spreads in the coming quarters [26][27] Question: Is the slowing loan repricing momentum specific to your portfolio or a larger market dynamic? - Management indicated it is both a larger market dynamic and observable in their portfolio, with a gradual slowing in loan repricing speeds [30][32] Question: How does the company view the ATM share issuance relative to the stock's trading position? - Management stated they continue to utilize the ATM when trading at a premium, noting the stock was trading at NAV [34]

Financial Data and Key Metrics Changes - In 2025, the company achieved a record Adjusted EBITDA of $497 million, representing a 7% increase year-over-year [4] - The fourth quarter saw a 47% increase in Adjusted EBITDA and a 340 basis point improvement in Adjusted EBITDA margin [18] - Gross profit for the fourth quarter increased by 27%, achieving a record gross margin of nearly 19% [18] Business Line Data and Key Metrics Changes - Aggregates volumes increased by 17% in the fourth quarter, with pricing up by 8% [18] - Ready-mix volumes rose by 20% in the fourth quarter, with gross margin lifting by 230 basis points [20] - Contracting services revenue grew by 15%, with the Mountain region experiencing nearly 20% growth [22] Market Data and Key Metrics Changes - The company entered 2026 with a record backlog of $1 billion, a 38% increase from the previous year [11] - Approximately 46% of IIJA funding remains to be disbursed across the company's 14 states, indicating strong public budgets [11] - The company is seeing increased private opportunities, including data centers and distribution facilities [11] Company Strategy and Development Direction - The company focuses on four growth components: markets, vertical integration, self-help initiatives, and a strong corporate culture [6] - The acquisition program ramped up in 2025 with five completed deals, and the company expects another busy year in 2026 [4][7] - The strategy emphasizes being an aggregates-based, end-to-end provider to enhance value and improve margins [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence entering 2026, citing strong momentum and favorable market conditions [5] - The company anticipates continued growth driven by infrastructure investments and a disciplined focus on cost control and pricing optimization [10][25] - Management expects consolidated revenue for 2026 to be between $3.3 billion and $3.5 billion, with Adjusted EBITDA between $520 million and $560 million [26] Other Important Information - The company invested $789 million in growth initiatives in 2025, including acquisitions and organic projects [23] - Maintenance capital expenditures were $170 million, or 6% of revenue, consistent with previous guidance [24] - The company ended the year with nearly $75 million in unrestricted cash and a net leverage position of 2.2x [25] Q&A Session Summary Question: Opportunities to build on backlog in the West region - Management acknowledged a geographic shift in backlog but expressed confidence in California, Hawaii, and Alaska's funding [32] Question: Potential levers to outperform aggregate pricing expectations - Management highlighted the success of dynamic pricing strategies and ongoing training to optimize pricing [38] Question: Margin outlook for 2026 - Management indicated expected margin improvements across all product lines, driven by dynamic pricing and operational excellence initiatives [44] Question: Return to year-over-year growth in Oregon - Management expects Oregon's performance in 2026 to be broadly in line with 2025 results, pending clarity on public funding [48] Question: Contribution of acquisitions to 2026 growth - Management stated that the full-year contribution from TexCrete would offset seasonal losses from Strata, indicating strong organic growth [90]

Financial Data and Key Metrics Changes - Kite Realty Group reported $0.52 of NAREIT FFO per share and $0.51 of Core FFO per share in Q4 2025, with full-year results of $2.10 and $2.06 respectively, reflecting a 3.5% year-over-year growth in Core FFO per share [15][16] - Same property NOI growth for the full year was 2.9%, exceeding original guidance by 115 basis points, with an average growth of 4% over the past four years [16][19] - The company maintained a net debt to EBITDA ratio of 4.9 times, below its long-term target range of 5-5.5 times [20] Business Line Data and Key Metrics Changes - The lease rate increased by 120 basis points sequentially, driven by strong demand, particularly from anchor tenants, with 9 anchor leases signed in Q4 and 28 for the full year [7][8] - Small shop lease rates increased by 50 basis points sequentially and 110 basis points year-over-year, indicating a steady upward trend over the last five years [8] Market Data and Key Metrics Changes - The company sold approximately $622 million of non-core assets, reducing the percentage of ABR from power centers by 400 basis points and increasing exposure to neighborhood, grocery, lifestyle, and mixed-use assets [6][11] - The signed-not-open pipeline grew by $4 million sequentially to $37 million of NOI, with 70% expected to come online in 2026 [16] Company Strategy and Development Direction - The company aims to focus on higher long-term organic growth by shedding lower growth assets and negotiating better annual rent bumps, targeting 200 basis points of embedded escalators in the portfolio [9][12] - Development activities include a significant expansion at One Loudoun, adding retail, office, hotel, and multifamily units to a premier mixed-use asset [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the operational momentum and the ability to capitalize on it in 2026 and beyond, emphasizing the importance of optimizing and de-risking the portfolio [15][20] - The guidance for 2026 includes NAREIT and Core FFO per share ranges between $2.06 and $2.12, with expectations of lower growth in the first half of the year followed by acceleration [17][18] Other Important Information - The company executed $300 million in stock buybacks at a significant discount to NAV, viewing it as a clear yield arbitrage opportunity [7][12] - The balance sheet remains strong with over $1 billion in liquidity, allowing for flexibility in capital allocation [20] Q&A Session Summary Question: Expectations on non-core dispositions pricing - Management indicated that pricing for non-core dispositions would be similar to 2025, with a healthy market demand for such products [24] Question: 1031 acquisitions product type - The focus remains on moving away from larger format centers towards neighborhood grocery and lifestyle mixed-use assets, with considerations for tax management [26][28] Question: Key factors driving guidance range - Factors include lower bad debt, rent commencement dates, and timing of transactional activities, with a focus on visibility for guidance [33][34] Question: Update on City Center disposition - The City Center is actively being remarketed, with a weighted average transactional date expected in August [41] Question: Broader acquisition environment - The market is active with strong bids across retail, and the company is underwriting several opportunities while focusing on embedded rent growth [44][45] Question: Components of bad debt expectations - A general reserve of 100 basis points was set, primarily due to specific tenants, with a focus on monitoring the situation throughout the year [50][51] Question: Flow-through from same-property NOI to FFO growth - Limitations on flow-through are attributed to recurring unpredictable items and non-cash items from previous mergers, which are expected to normalize [66] Question: Share repurchase strategy - The company continues to evaluate share repurchases based on market conditions and the potential for future growth, maintaining a focus on a healthy balance sheet [70][71]

Financial Data and Key Metrics Changes - For the year 2025, the company reported diluted earnings per share of $6.55, a decrease of 9% from the previous year [5][18] - The company ended 2025 with $386 million in cash, maintaining a strong balance sheet and ample liquidity [20] - The company is initiating its 2026 diluted earnings per share guidance range with a midpoint of $5.42 [6][23] Business Line Data and Key Metrics Changes - Electric segment earnings increased over 7% year-over-year, driven by recovery of increased rate base investments and higher sales volumes [18] - Manufacturing segment earnings decreased by 16% year-over-year, primarily due to lower sales volumes and higher SG&A expenses [19] - Plastic segment earnings decreased by 15% year-over-year, largely driven by lower average sales prices [21] Market Data and Key Metrics Changes - The company’s electric rates remained well below the national and regional average, with 2025 residential electric rates being 34% below the national average [13] - The end market demand for the manufacturing segment faced headwinds, particularly in lawn and garden and agriculture sectors [14][15] Company Strategy and Development Direction - The company is committed to a customer-focused growth plan, with a reaffirmed five-year capital spending plan totaling $1.9 billion [24] - The company is increasing investments in renewable generation and battery storage, including a new battery storage project expected to be operational in 2028 [10][24] - The company targets a long-term earnings per share growth rate of 7%-9%, aiming for a total shareholder return of 10%-12% [28] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the electric segment's growth, expecting a 14% increase in earnings in 2026 due to higher returns from increased average rate base [21] - The company acknowledged challenges in the manufacturing segment but noted improvements in certain end markets [19][23] - Management highlighted the importance of strategic diversification to provide long-term benefits to customers and investors [29] Other Important Information - The company has a history of uninterrupted dividend payments for 88 consecutive years, with a recent 10% increase in dividends [5] - The company is facing competition from low-cost importers in the plastics segment, impacting pricing and sales [15][27] Q&A Session Summary - There were no questions during the Q&A session, and the call concluded without any inquiries from participants [31][32]

Financial Data and Key Metrics Changes - In Q4 2025, the company reported net sales of $567 million, EBITDA of $50 million, and adjusted diluted earnings per share of $0.03 [6][7] - For the full year, net sales reached $2.7 billion, with EBITDA of $436 million and adjusted earnings per share of $2.65 [16][17] - The EBITDA margin for the siding business improved to 26%, up 1 percentage point from 2024 [15] Business Line Data and Key Metrics Changes - The siding business grew by 8% for the full year, with a 4% increase in both net selling prices and sales volumes [7][15] - ExpertFinish saw a significant volume increase of 35% in Q4, while prime volumes declined by 5% [13] - OSB operations faced challenges with a year-over-year revenue decrease of $129 million and EBITDA decline of $95 million due to unfavorable supply-demand dynamics [15] Market Data and Key Metrics Changes - Single-family housing starts were down approximately 10% in Q3 2025, with further weakness expected in Q4 [6] - The company noted a stronger market presence in the Upper Midwest, which helped mitigate impacts from softer markets in the Southeast [9] - OSB prices reached their lowest levels in 20 years, significantly impacting revenue [10] Company Strategy and Development Direction - The company aims to drive growth, gain market share, and deliver product innovation while generating shareholder value [5] - Integration of operations under a chief commercial officer and chief operating officer structure is expected to enhance sales synergies and operational efficiency [11] - The company plans to invest approximately $400 million in capital expenditures for 2026, focusing on sustaining maintenance and strategic growth [23] Management's Comments on Operating Environment and Future Outlook - Management acknowledged affordability challenges due to tariffs and economic uncertainty affecting consumer confidence [5] - The company anticipates a difficult first quarter in 2026, with expected volume declines of 15%-20% [20] - Despite current challenges, management remains confident in the long-term growth potential of the SmartSide product line [24] Other Important Information - The company achieved a total incident rate of 0.62 in 2025, earning the APA's Safest Company Award for the third consecutive year [12] - The cash balance at year-end was $292 million, with an undrawn revolver of $750 million, providing over $1 billion in liquidity [17] Q&A Session Summary Question: What factors are influencing siding revenue guidance? - Management expects improvement in shed demand to be the dominant factor, alongside overall housing normalization [27][28] Question: Are there risks of a shift to lower-cost siding materials? - Affordability remains a headwind, with some movement towards vinyl, but the company believes in the value of its SmartSide offerings [29][30] Question: What is the demand outlook for the ExpertFinish product? - Demand remains strong, with macro trends favoring the product, and the company has come off allocation due to operational improvements [33][34] Question: How is the competitive environment in siding evolving? - The company is gaining market share across segments, with a focus on new construction and repair/remodel markets [43][44] Question: What is the outlook for OSB demand and capacity management? - The company is focused on matching supply with demand, with optimism for a rebound in prices and demand as the building season approaches [69][70]

Financial Data and Key Metrics Changes - Revenue for the second quarter was $116,000, compared to $0 in the same period last year, primarily from cost reimbursements under a collaboration agreement with Boehringer Ingelheim [6] - Total operating expenses increased to $7.4 million from $2.6 million in the prior year, driven by higher investments in obesity development programs and increased compensation costs [6][7] - Net loss for the quarter was $7.3 million, or $2.86 per share, compared to a net loss of $2.4 million, or $5.92 per share in the comparable period last year [8] - Cash and cash equivalents as of December 31, 2025, were $14.5 million, up from $1.3 million at September 30, 2025 [9] Business Line Data and Key Metrics Changes - The company is advancing its melanocortin-4 receptor-based obesity pipeline, focusing on rare syndromic and genetic obesity disorders [10] - The lead oral small molecule MC4R agonist, PL7737, is progressing through IND-enabling toxicology studies, with an IND submission planned for the first half of 2026 [11] - The next generation selective melanocortin-4 receptor peptide agonists are also being developed, with an IND submission planned for the second half of 2026 [11] Market Data and Key Metrics Changes - The company has regained compliance with NYSE American listing standards, and its common stock resumed trading under the symbol PTN [5][13] - The focus remains on rare neuroendocrine obesity disorders, including hypothalamic obesity and Prader-Willi syndrome, which represent significant unmet medical needs [10][12] Company Strategy and Development Direction - The company aims to deliver differentiated product profiles with a focus on enhancing patient tolerability and minimizing off-target effects [11] - A strategic shift was made by sub-licensing the dry eye disease clinical candidate, PL9643, to focus more on core obesity programs [12][13] - The company is positioned to pursue long-term value creation through multiple partnerships and a focused pipeline [13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the differentiation of their products, particularly regarding tolerability and safety profiles compared to current treatments [17][34] - The company anticipates moving into phase II studies for Prader-Willi syndrome and hypothalamic obesity patients by mid-2027 [43] - Management highlighted the importance of combination therapies with GLP-1 based treatments as the market evolves [48] Other Important Information - The company completed a public offering of $18.2 million, strengthening its balance sheet and providing capital for advancing obesity programs [5][10] - The company expects its cash runway to extend beyond March 31, 2027, based on current operating plans [9] Q&A Session Summary Question: What preclinical signals give confidence in differentiation for PL7737? - Management highlighted the design of the compound to be more selective for the melanocortin-4 receptor, which should reduce hyperpigmentation and control GI side effects [17] Question: How will patient selection and endpoints be defined for phase one studies? - The focus will be on safety and confirming oral absorption, with weight reduction and control of hyperphagia as key metrics in the multiple-ascending dose study [19][20] Question: Is there an increased emphasis on Prader-Willi syndrome? - Management confirmed that while it has always been in the background, there is a focus on larger indications like hypothalamic obesity and Prader-Willi syndrome due to the number of patients [22] Question: How will the oral small molecule and weekly injection be positioned? - Both products are seen as complementary, with each suited for different patient populations [24][25] Question: What is the anticipated cash flow for the next quarters? - Management indicated that there were one-time extraordinary expenses in the previous quarter, and they expect operating expenses to decrease in the upcoming quarters [27][28]

Financial Data and Key Metrics Changes - In Q4 2025, the company reported net sales of $567 million, EBITDA of $50 million, and adjusted diluted earnings per share of $0.03 [6][7] - For the full year, net sales reached $2.7 billion, with EBITDA of $436 million and adjusted earnings per share of $2.65 [16][17] - The EBITDA margin for the siding business improved to 26%, up 1 percentage point from the previous year [15] Business Line Data and Key Metrics Changes - The siding business grew by 8% for the full year, with a 4% increase in net selling prices and a 4% increase in sales volumes [7][15] - ExpertFinish product line saw an impressive 35% growth in Q4, while prime volumes declined by 5% [13] - OSB segment faced significant challenges, resulting in a year-over-year decrease of $129 million in revenue and $95 million in EBITDA due to unfavorable supply-demand dynamics [15] Market Data and Key Metrics Changes - Single-family housing starts were down approximately 10% in Q3 2025, with further weakness expected in Q4 [6][10] - The company noted a stronger market presence in the Upper Midwest, which helped mitigate impacts from softer markets in the Southeast [9] - OSB prices reached their lowest levels in 20 years, significantly impacting the segment's performance [10] Company Strategy and Development Direction - The company is focused on driving growth, gaining market share, and delivering product innovation while managing costs effectively [5][10] - Integration of operations under a chief commercial officer and chief operating officer structure is expected to enhance sales synergies and operational efficiency [11] - Capital investments are being adjusted in response to market conditions, with a focus on sustaining maintenance and strategic growth [23] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges posed by tariffs, economic policy uncertainty, and deteriorating consumer confidence affecting housing affordability [5][6] - The company anticipates a difficult first quarter of 2026, with expected declines in total volumes of 15%-20% [20] - Despite current challenges, management remains optimistic about long-term growth potential, particularly in the siding segment [24] Other Important Information - The company achieved a total incident rate of 0.62 in 2025, earning the APA's Safest Company Award for the third consecutive year [12] - The cash balance at year-end was $292 million, with an undrawn revolver of $750 million, providing over $1 billion in liquidity [17] Q&A Session Summary Question: What factors are influencing siding revenue guidance? - Management expects improvement in shed demand to be the dominant factor, alongside overall housing normalization [26][27] Question: Are there risks of a shift to lower-cost siding materials? - Affordability remains a headwind, with some movement towards vinyl, but the company believes in the value of its SmartSide products [28][29] Question: What is the demand outlook for the ExpertFinish product? - Demand remains strong due to macro trends, and the company has come off allocation due to operational improvements [31][32] Question: How is the competitive environment in siding evolving? - The company is confident in gaining market share across segments, despite challenges in the housing market [40][41] Question: What is the outlook for OSB demand and capacity management? - The focus is on matching supply with demand, with optimism for a rebound in pricing due to competitor mill closures [66][67]

Kite Realty Group Trust (NYSE:KRG) Q4 2025 Earnings call February 17, 2026 11:00 AM ET Company ParticipantsBrian McCarthy - Senior Vice President, Corporate Marketing and CommunicationsHeath Fear - EVP and CFOJohn Kite - Chairman and CEOTom McGowan - President and COOConference Call ParticipantsAlexander Goldfarb - AnalystAndrew Reale. - Vice President and AnalystCooper Clark - AnalystCraig Mailman - Managing Director and REIT AnalystFloris van Dijkum - Managing Director and Senior Research AnalystHongliang ...